Home > Oncology > ASCO GU 2022 > Renal Cell Carcinoma > High-risk early RCC may benefit from neoadjuvant avelumab plus axitinib

High-risk early RCC may benefit from neoadjuvant avelumab plus axitinib

Presented By
Dr Axel Bex, Netherlands Cancer Institute, the Netherlands

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASCO GU 2022
Trial
Phase 2, NeoAvAx
Results of the NeoAvAx trial indicated that the neoadjuvant combination of immune checkpoint inhibitor avelumab plus VEGF inhibitor axitinib has potential for patients with high-risk, non-metastatic, clear-cell renal cell carcinoma (RCC). Five-year recurrence rates of 60% in patients with high-risk RCC following nephrectomy pose a clinical unmet need [1]. Antibodies targeting PD-1/PD-L1 combined with vascular endothelial growth factor (VEGF) inhibitors are a first-line standard of care for metastatic RCC [2]. Neoadjuvant use of these combinations may lead to downstaging and reduce the risk of recurrence. The NeoAvAx study (NCT03341845) aimed to evaluate the efficacy and safety of neoadjuvant avelumab plus axitinib in patients with high-risk RCC. It is a single-arm, phase 2 trial of 12 weeks neoadjuvant avelumab/axitinib prior to nephrectomy. The study enroll...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on